oxophenylarsine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
oxophenylarsine: inhibits protein-tyrosine-phosphatase
phenylarsine oxide : An arsine oxide derived from phenylarsine.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oetken, C | 1 |
| von Willebrand, M | 1 |
| Autero, M | 1 |
| Ruutu, T | 1 |
| Andersson, LC | 1 |
| Mustelin, T | 1 |
1 other study available for oxophenylarsine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Phenylarsine oxide augments tyrosine phosphorylation in hematopoietic cells.
Topics: Aged; Animals; Arsenicals; Blood Platelets; Busulfan; Cell Line; Dithiothreitol; Gene Rearrangement; | 1992 |